MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
September 15, 2024 03:00 ET
|
MacroGenics, Inc.
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing...
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
August 06, 2024 16:01 ET
|
MacroGenics, Inc.
Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in SeptemberReceived $100.0 million in milestones related to Incyte’s advancement of ZYNYZ®...
MacroGenics to Participate in Upcoming Investor Conference
June 11, 2024 07:45 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
May 13, 2024 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
May 09, 2024 16:01 ET
|
MacroGenics, Inc.
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09,...
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
April 03, 2024 16:30 ET
|
MacroGenics, Inc.
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data,...
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
March 07, 2024 16:01 ET
|
MacroGenics, Inc.
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I...
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
February 27, 2024 17:45 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics to Participate in Upcoming Investor Conference
January 08, 2024 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
August 09, 2023 16:01 ET
|
MacroGenics, Inc.
Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50...